Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:58 PM
Ignite Modification Date:
2025-12-24 @ 12:58 PM
NCT ID:
NCT00070161
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria:
* No radiographic evidence of disease
* Stable disease, defined as no tumor progression within the past 3 months
* Previously treated with 1 course of localized or whole brain radiotherapy of at least 3,000 cGy at least 6 months before study registration
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* Karnofsky 70-100%
Life expectancy
* At least 30 weeks
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* Not pregnant or nursing
* Negative pregnancy test
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* No concurrent chemotherapy
Endocrine therapy
* Concurrent steroid therapy allowed if on stable or decreasing dose
Radiotherapy
* See Disease Characteristics
* No concurrent cranial radiotherapy
Surgery
* No concurrent surgery
Other
* More than 3 months since prior donepezil or EGb761
* No concurrent donepezil (group 2 only)
* No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)
* No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or enoxaparin) (group 2 only)
* No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)
* No other concurrent therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
120 Years
Study:
NCT00070161
Study Brief:
Protocol Section:
NCT00070161